MHLW Approves Additional Indication For Taiho's Protecadin
This article was originally published in PharmAsia News
Executive SummaryTaiho Pharmaceutical received an additional indication approval in Japan for Protecadin (lafutidine) to treat reflux esophagitis. The approval was based on a Phase III study in which lafutidine demonstrated significant improvement in symptoms compared to placebo. Originally approved in 2000 for gastric ulcer, duodenal ulcer, acute and chronic gastritis, Protecadin achieved ¥7.5 billion in sales in 2009. (Click here for more - Japanese language)"Taiho Obtains Additional Indication Of Reflux Esophagitis For Protecadin" - CB News (3/15/2010)
You may also be interested in...
The first phase of a major trade agreement just signed by the US and China obliges the latter to implement a system linking pharma patent enforcement to marketing authorization procedures as well as to offer patent-term extensions.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.